Mangrove Partners IM LLC Purchases Shares of 2,797 Stryker Corporation $SYK

Mangrove Partners IM LLC purchased a new stake in shares of Stryker Corporation (NYSE:SYK) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 2,797 shares of the medical technology company’s stock, valued at approximately $983,000.

Several other large investors have also added to or reduced their stakes in SYK. Brighton Jones LLC lifted its holdings in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares in the last quarter. Schnieders Capital Management LLC. purchased a new position in Stryker during the second quarter valued at approximately $205,000. Marshall Wace LLP lifted its holdings in Stryker by 107.9% during the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after purchasing an additional 77,831 shares in the last quarter. Nebula Research & Development LLC purchased a new position in shares of Stryker in the second quarter worth $219,000. Finally, HUB Investment Partners LLC purchased a new position in shares of Stryker in the second quarter worth $253,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Stryker stock opened at $310.71 on Wednesday. The company has a market cap of $119.11 billion, a price-to-earnings ratio of 35.96, a PEG ratio of 1.97 and a beta of 0.78. The firm’s fifty day moving average is $315.51 and its 200 day moving average is $342.88. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the company earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts forecast that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is presently 40.74%.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the sale, the vice president directly owned 177 shares in the company, valued at approximately $50,170.65. The trade was a 95.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 over the last 90 days. 4.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

SYK has been the topic of several research analyst reports. BTIG Research lowered their target price on shares of Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Robert W. Baird set a $385.00 target price on shares of Stryker in a report on Friday, May 1st. Truist Financial reissued a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, William Blair reissued an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $395.33.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.